Associated Papers
Identifying prognostic biomarkers for palbociclib add-on therapy in fulvestrant-resistant breast cancer using cell-free DNA sequencing.
Takeshita T et al.
Esmo Open, 2024
38387111 (PubMed )
Supplement: mmc2.xlsx › Baseline
Exemestane plus everolimus and palbociclib in metastatic breast cancer: clinical response and genomic/transcriptomic determinants of resistance in a phase I/II trial.
Gómez Tejeda Zañudo J et al.
Nature Communications, 2024
Somatic estrogen receptor α mutations that induce dimerization promote receptor activity and breast cancer proliferation.
Irani S et al.
The Journal of Clinical Investigation, 2024
37883178 (PubMed )
Supplement: jci-134-163242-s231.xlsx › TableS5
Circulating tumor DNA landscape and prognostic impact of acquired resistance to targeted therapies in cancer patients: a national center for precision medicine (PRISM) study.
Bayle A et al.
Molecular Cancer, 2023
37924050 (PubMed )
Supplement: 12943_2023_1878_MOESM2_ESM.xlsx › Feuil1
Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients.
Pascual J et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2023
37490393 (PubMed )
Supplement: ccr-23-0956_supplementary_table_s2_suppts2.xlsx › PEARL_baseline_mutations
Covalent ERα Antagonist H3B-6545 Demonstrates Encouraging Preclinical Activity in Therapy-Resistant Breast Cancer.
Furman C et al.
Molecular Cancer Therapeutics, 2022
Genomic profile of advanced breast cancer in circulating tumour DNA.
Kingston B et al.
Nature Communications, 2021
33893289 (PubMed )
Supplement: 41467_2021_22605_MOESM4_ESM.xlsx › SNVs_Indels
Circulating tumour DNA in metastatic breast cancer to guide clinical trial enrolment and precision oncology: A cohort study.
Zivanovic Bujak A et al.
Plos Medicine, 2020
33001984 (PubMed )
Supplement: pmed.1003363.s013.xlsx › S4_Table
Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer.
Hartmaier RJ et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology, 2018
29360925 (PubMed )
Supplement: mdy025_suppl_data.zip › mdy025_Supplementary_Tables.xlsx › SupplTable7
Powerful dominant negative mutants of the human estrogen receptor.
Ince BA et al.
The Journal of Biological Chemistry, 1993
Select a paper to view details